Acambis retains neutral rating from Merrill

Acambis plc was retained at its neutral rating by Merrill Lynch analyst Peter Welford. The company has not yet been awarded either of two potential smallpox vaccine U.S. government contracts. Merrill assumes that Acambis and Bavarian Nordic will be awarded 20 million dose contracts, worth about $350 million each, but not until the second quarter of this year. Future contracts could be worth as much as $1.5 billion. Shares of the Cambridge, U.K., pharmaceutical company were down 24 cents, or 3.22%, at $7.21 on volume of 22,000 shares versus the three-month running average of 34,273 shares. (Nasdaq: ACAM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.